BDX

Becton, Dickinson and Company

Next est. report 2026-11-05 · BMO

GLP-1 Long '24: GLP1 Equip/Distrib MedTech Long '26: Diagnostics & Early Detection TrumpPolicy PreElection Long '24: Tariff Winners

Loading…

Loading chart…

Overview

Becton, Dickinson and Company (BDX) is a global medical technology firm providing essential medical supplies, devices, and equipment. Its four segments—Medical

Becton, Dickinson and Company (BDX) is a global medical technology firm providing essential medical supplies, devices, and equipment. Its four segments—Medical Essentials (34%), Interventional (28%), Connected Care (24%), and BioPharma Systems (13%)—serve healthcare providers, researchers, and pharmaceutical companies worldwide, focusing on medication delivery, surgical products, infusion systems, and drug delivery, respectively.

Search Keywords Brand Product

PureWick
Alaris infusion pump
HemoSphere Alta
Liverty TIPS Stent Graft
Elyra Thulium Fiber Laser System
Acumen IQ Plus Finger Cuff
BD Vacutainer
Rowa Pharmacy Automation
Vystra injection pen
Pyxis Pro
BD Incada
medical technology
drug delivery systems
patient monitoring devices
surgical devices
diagnostics products
GLP-1 therapies
pharmacy automation
vascular access management
infection prevention
advanced tissue regeneration
medical supplies
infusion therapy

Search Keywords Event Phrases

BD earnings
BD guidance
BD Investor Day

Search Keywords Policy Regulatory

tariffs impact
Medicare reimbursement
FDA approval medical devices

What They Do (Plain English & Analogies): BD (Becton, Dickinson and Company) is like a comprehensive toolkit for hospitals and healthcare providers worldwide. They make a vast array of essential medical products, from the everyday items like syringes and needles for giving shots, to advanced equipment for surgery, patient monitoring, and diagnosing diseases. Think of them as providing much of the 'plumbing' and 'instrumentation' that keeps a hospital running, helping doctors and nurses deliver care, manage medications, and perform tests. They also create specialized systems for drug delivery, including those for new powerful medicines like GLP-1s, and automation solutions for pharmacies.
Very Brief History: Founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson, Becton, Dickinson and Company later moved its headquarters to Franklin Lakes, New Jersey. Over its long history, BD has grown into a global medical technology leader through continuous innovation and strategic acquisitions, such as CareFusion in 2014 and C. R. Bard in 2017. In recent years, the company has undergone significant portfolio reshaping, including the spin-off of its diabetes care business (Embecta Corporation) in 2022 and its Life Sciences business (in combination with Waters Corporation) in February 2026, to become a more focused 'New BD' medical technology company.
"Street Stereotype": The 'Street stereotype' for BDX has historically been that of a large, diversified medical conglomerate with a massive corporate footprint in traditional hospital hardware like syringes and catheters. While recognized for its solid molecular diagnostics arm, this was often seen as diluted by its broader portfolio, leading to a perception that it lacked the explosive upside and pure-play exposure of more specialized early-detection or diagnostics companies. However, with the recent spin-off of its Life Sciences business, the company is actively working to redefine itself as a more focused med tech company, aiming to demonstrate enhanced growth and earnings potential.
Subsidiaries On Linked In*: BD Medical — Division focused on medication management and delivery; LinkedIn: BD Medical
BD Interventional — Division focused on minimally invasive surgical and interventional procedures; LinkedIn: BD Interventional
BD Biosciences — Division focused on cell analysis and research tools, part of the broader Life Sciences offerings that remain with BD after the spin-off; LinkedIn: BD Biosciences
Rowa Technologies — Brand/entity focused on pharmacy automation, acquired by BD; LinkedIn: Rowa Technologies
Customer Sectors & Example Clients: BD's customers span a wide range of healthcare sectors, including healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public. Specific client types mentioned or implied include hospitals (operating rooms, intensive care units), government healthcare channels (e.g., the Veterans Administration for PureWick products), and pharmaceutical companies. An example client mentioned is EMS, one of Brazil's leading pharmaceutical companies, with whom BD has a collaboration for GLP-1 therapies. Based on their business model, other likely clients would include major hospital networks (e.g., HCA Healthcare, Mayo Clinic), large pharmaceutical manufacturers, and independent clinical laboratories.
New Customers / Segments They'Re Targeting: BD is actively targeting several new customer sets and market segments. They are focused on expanding their reach to underserved OR and ICU patients with noninvasive monitoring technologies. The company is also making significant inroads into the biologics market, particularly with GLP-1 therapies, signing approximately 100 agreements with new customers for novel and biosimilar GLP-1 programs. Furthermore, BD is investing in market development for its PureWick platform, including seeking reimbursement for at-home use, which would expand its customer base beyond traditional institutional settings. They are also enhancing commercial execution in key growth platforms like Advanced Patient Monitoring and Peripheral Intervention through increased sales team investments.
Supply Chain And Sourcing Geographies: BD operates a global supply chain, which it describes as one of the most resilient in the industry, achieving high service levels and low back orders. The company is focused on operational excellence through 'BD Excellence,' which includes plant consolidations, raw material savings, and waste reduction. They are also investing in a standardized digital platform to deploy AI across their end-to-end supply chain for improved productivity and service. While specific sourcing countries are not detailed in the transcript, the mention of a 110 basis point tariff impact on adjusted operating margin indicates significant international sourcing and exposure to global trade policies. Public information suggests BD has manufacturing operations in various countries, including the US, Mexico, Brazil, Canada, the Dominican Republic, France, Germany, Hungary, India, and Japan.
Sales Geographies And Expansion Plans: BD sells its products globally, serving customers around the world. The company reported strong performance in the U.S. across its MDS and specimen management portfolios. While facing continued pressure in China, this market now represents a much smaller portion of BD's revenue (down to approximately 4% of New BD revenue). BD is actively expanding its sales presence, as evidenced by the early European launch of the Liverty TIPS Stent Graft and the commercial availability of new noninvasive monitoring technologies in both the U.S. and Europe. They also announced a new collaboration with EMS in Brazil for a semaglutide therapy utilizing their Vystra injection pen, indicating expansion in Latin American healthcare markets. Furthermore, efforts to secure reimbursement for at-home use of PureWick suggest plans to expand into home care settings.
How Key Themes May Help/Hurt: The 'MedTech Long '26: Diagnostics & Early Detection' theme presents a mixed impact for BDX. While BD has a molecular diagnostics arm and its specimen management business is performing strongly, its broad corporate footprint in other medical hardware might dilute its 'explosive upside' compared to pure-play diagnostic companies. However, BD's investments in AI for its supply chain and AI features in products align with the theme's focus on technological advancements in genomics and AI. The 'GLP-1 Long '24: GLP1 Equip/Distrib' theme is a significant positive for BDX, as the company is directly benefiting from the rising demand for GLP-1 drugs, with double-digit growth in biologics driven by GLP-1s and numerous agreements signed for GLP-1 programs. The 'TrumpPolicy PreElection Long '24: Tariff Winners' theme suggests BDX might have some insulation against tariffs due to its diversified nature, but the transcript explicitly mentions a 110 basis point tariff impact on adjusted operating margin, indicating that tariffs can still hurt profitability.

3 Main Long-Term Bull Details

Growth Platform Momentum and Innovation: BD is experiencing strong, broad-based growth across its key platforms, including biologic drug delivery (especially GLP-1s), advanced patient monitoring, PureWick, advanced tissue regeneration, peripheral vascular disease, and Rowa pharmacy automation. The company is actively investing in and launching innovative products within these high-growth areas, such as the Liverty TIPS Stent Graft and the Elyra Thulium Fiber Laser System, which are expected to fuel sustained revenue acceleration.
Operational Excellence and Margin Expansion: The 'BD Excellence' operating system is consistently driving significant productivity gains (approximately 8% gross productivity in plants) and improving gross and operating margins through plant consolidations, raw material savings, waste reduction, and higher efficiencies. The ongoing investment in AI for the supply chain is anticipated to provide further meaningful runways for productivity and service improvement, contributing to long-term margin expansion.
Strategic Focus as 'New BD' and Capital Allocation: Following the spin-off of its Life Sciences business, BD is operating as a more focused med tech company. This strategic clarity allows for disproportionate reallocation of R&D and commercial investments into the highest-growth sectors, enhancing customer partnerships and driving sustainable share gains. The company's disciplined capital allocation framework, including share repurchases and selective high-growth tuck-in M&A, is supported by improving free cash flow, providing firepower for future growth.

3 Main Long-Term Bear Details

Lingering Headwinds and Transitionary Pressures: BD faces defined headwinds from the Alaris remediation, which is expected to create a 200 basis point revenue headwind in fiscal year 2027, and ongoing pressure from vaccines in China. While these are expected to be temporary, they will continue to impact top-line growth in the near to medium term.
Macroeconomic and Geopolitical Volatility: The company is exposed to dynamic macroeconomic environments, including potential inflation impacting input costs (such as oil-based resins for plastics) and geopolitical factors like tariffs, which have already impacted operating margins. While BD is taking proactive pricing actions, sustained or escalating cost pressures could challenge profitability.
Intense Competition and Need for Continuous Innovation: Operating in a highly competitive medical technology market, BD must continuously innovate and execute commercially to maintain and gain market share. Competitors are active across its segments, and the company's ability to consistently deliver breakthrough products and maintain strong commercial execution will be critical to offsetting competitive pressures and ensuring long-term growth.

Competitors And Differentiation: BD operates in a highly competitive medical technology industry, facing competition from large multinational corporations and specialized companies. While specific competitors aren't always named in the transcript, the company's focus on share gains in areas like Alaris infusion systems and BD Vacutainer specimen management implies competition in those markets. Competitors in the broader medical device and diagnostics space include companies like Medtronic, Thermo Fisher Scientific, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Baxter International, and Stryker. BD differentiates itself through its 'New BD' strategy, emphasizing a more focused portfolio and accelerated growth in key platforms. Its competitive positioning is built on commercial excellence, driving product innovation (e.g., Liverty TIPS Stent Graft, Elyra Thulium Fiber Laser System, Acumen IQ Plus Finger Cuff with AI features), and operational excellence through 'BD Excellence,' which ensures a resilient supply chain and consistent service. The company also highlights its strong positions in high-growth areas like biologic drug delivery, including GLP-1s, and advanced patient monitoring.
Recent Performance & What The Market'S Focused On: BD delivered a strong third fiscal quarter of 2026, with revenue of $5 billion, up 4.4% (FX-neutral), adjusted operating margin of 24.9%, and adjusted EPS of $3.23, which was ahead of expectations. Performance was broad-based, driven by double-digit growth in key platforms like biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration. The company raised its full-year guidance, now expecting revenue growth toward the high end of its low single-digit range and raising the midpoint of its adjusted EPS guidance. The market is currently focused on the continued momentum of BD's growth platforms, the impact and duration of known headwinds (Alaris remediation, China, vaccines), the company's ability to expand operating margins through 'BD Excellence,' and the outlook for fiscal year 2027, particularly regarding the Alaris headwind and potential for EPS leverage.

Revenue Segments And Estimated Mix: Medical Essentials — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Grew 3.2% in Q3 2026, with strong U.S. performance in MDS and specimen management, partially offset by China pressure.
Connected Care — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Grew 4.4% in Q3 2026, led by double-digit growth in advanced patient monitoring and low single-digit growth in MMS, partially offset by difficult prior year comparison in Alaris capital.
BioPharma Systems — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Grew 5.2% in Q3 2026, driven by continued double-digit growth in biologics (led by GLP-1s), partially offset by lower demand for vaccine products. Excluding vaccines, grew mid-teens.
Interventional — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Grew 5.5% in Q3 2026, with solid mid-single-digit growth across the segment, led by PI (oncology, peripheral vascular disease), UCC (PureWick), and Surgery (infection prevention, advanced tissue regeneration).
Product Brands: PureWick
Alaris
HemoSphere Alta
Smart Recovery
Liverty TIPS Stent Graft
Elyra Thulium Fiber Laser System
Acumen IQ Plus Finger Cuff
Smart Pressure Controller
BD Vacutainer
Rowa Pharmacy Automation
Vystra injection pen
Pyxis Pro
BD Incada
3DMax
AccuCath Ace
AllPoints
Arctic Sun
ArcticGel
Arista
Aspirex
Atlas
Avitene
BBS Revolution
BD Affirm
BD Angiocath
BD Aptra
BD BACTEC
BD BBL
BD COR
BD Cathena
BD CentroVena One
BD CentroVena
BD ChloraPrep
BD CultureSwab
BD CytoRich
BD Difco
BD E-Z Scrub
BD Eclipse
BD EleVation
BD Epilor
BD Falcon
BD FecalSwab
BD FocalPoint
BD GasPak
BD HealthSight
BD Hycheck
BD Insyte-N
BD Insyte-W
BD Insyte
BD Insyte Autoguard
BD Intramedic
BD Introsyte
BD Lactinex
BD MAX
BD MGIT
BD Macro-Vue

Bull / Bear Details

Becton, Dickinson and Company (BDX) is demonstrating strong execution and strategic focus post-spin-off, driving broad-based growth across key platforms like bi

Thesis

Becton, Dickinson and Company (BDX) is demonstrating strong execution and strategic focus post-spin-off, driving broad-based growth across key platforms like biologic drug delivery, advanced patient monitoring, and surgical solutions. Operational excellence through BD Excellence and targeted innovation are fueling margin expansion and market share gains. While temporary Alaris, China, and vaccine headwinds persist, their defined nature and the company's robust pipeline and commercial investments position BDX for sustained performance. (Updated: 2026-08-15)

Bull case

BD's "New BD" strategy is yielding broad-based growth, with over 90% of its portfolio delivering high single-digit growth and several key platforms (e.g., biologic drug delivery, APM, PureWick) achieving double-digit expansion. Targeted commercial investments are directly translating into market share gains and accelerated growth, exemplified by Alaris share gains and APM's growth rate increase.
Operational excellence through BD Excellence continues to drive significant productivity gains, with 8% gross productivity improvements in plants quarterly. Strategic investments in AI for the end-to-end supply chain and G&A functions are expected to further enhance efficiencies, improve cash flow, and contribute to sustained operating margin expansion, effectively mitigating external cost pressures like tariffs.
BD is strategically innovating and expanding its presence in attractive, high-growth markets. Recent product launches, such as the Liverty TIPS Stent Graft in the $2 billion global venous market and the Elyra Thulium Fiber Laser System in the $1.5 billion endourology market, along with advancements in noninvasive monitoring, demonstrate a focused pipeline designed to strengthen long-term growth.

Bear case

The Alaris remediation remains a significant, albeit defined, headwind, projected to create a 200 basis point drag on revenue growth in fiscal year 2027. This, coupled with ongoing pressure from vaccine demand and China market dynamics, concentrates headwinds on a portion of the portfolio, requiring strong performance from other segments to offset the impact.
Tariffs continue to exert pressure on profitability, evidenced by a 110 basis point impact on adjusted operating margin in the recent quarter. While BD is implementing pricing actions, persistent inflation in input costs, particularly for oil-based resins and freight, could continue to challenge gross and operating margins, necessitating continuous and effective productivity offsets.
Despite strong reported share gains, the medical technology market is intensely competitive across BD's diverse segments. Furthermore, the broader diagnostics and medical device industry faces persistent reimbursement pressures and evolving payer policies, which could impact the market uptake and profitability of both existing and newly launched products, particularly in areas requiring novel coverage.

Bull / Bear Case

Bear Case: BDX faces significant, albeit defined, headwinds from the Alaris remediation, projected to create a 200 basis point drag on revenue growth in fiscal year 2027. This, combined with ongoing pressure from vaccine demand and China market dynamics, concentrates headwinds on a portion of the portfolio, requiring strong performance from other segments to offset the impact. Tariffs continue to exert pressure on profitability, evidenced by a 110 basis point impact on adjusted operating margin in the recent quarter. Persistent inflation in input costs, particularly for oil-based resins and freight, could continue to challenge gross and operating margins, necessitating continuous and effective productivity offsets. The medical technology market remains intensely competitive across BD's diverse segments, and the broader industry faces persistent reimbursement pressures and evolving payer policies.
Bull Case: Becton, Dickinson and Company's "New BD" strategy is demonstrating strong execution, with over 90% of its portfolio delivering high single-digit growth and several key platforms, including biologic drug delivery (especially GLP-1s), advanced patient monitoring (APM), and PureWick, achieving double-digit expansion. Targeted commercial investments are directly translating into market share gains and accelerated growth. Operational excellence through BD Excellence continues to drive significant productivity gains, with 8% gross productivity improvements in plants quarterly, and strategic investments in AI for the supply chain are expected to further enhance efficiencies and contribute to sustained operating margin expansion. The company is strategically innovating and expanding its presence in attractive, high-growth markets with recent product launches like the Liverty TIPS Stent Graft and Elyra Thulium Fiber Laser System, strengthening its long-term growth profile.
More Compelling & Why: Bull. Despite a slightly elevated forward P/E ratio of approximately 29x compared to the Medical Instruments & Supplies industry average of around 26x, the bull case is more compelling. The company's strong Q3 performance, raised guidance, and the clear, time-bound nature of the Alaris headwind (ending in FY27) suggest the market is looking past near-term drags. The underlying double-digit growth in key platforms like GLP-1 biologics and Advanced Patient Monitoring, coupled with consistent operational efficiency gains from BD Excellence and strategic innovation, provides a robust foundation for sustained growth and margin expansion. My view would flip if the Alaris headwind persists beyond FY27 or if the company fails to translate its strong growth platform momentum into meaningful operating margin expansion.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
GLP-1 Program Growth and New Agreements	BD's strong position in biologic drug delivery, particularly for GLP-1s, is a significant growth driver. Continued expansion in this high-growth market through new agreements and product launches will accelerate revenue and improve product mix.	Announcements of new customer agreements for GLP-1 programs exceeding the current 100 agreements, specific product launches utilizing BD's delivery systems (e.g., Vystra pen), and reported double-digit growth rates in the BioPharma Systems biologics segment.	Bullish if BD continues to announce new GLP-1 agreements that significantly exceed 100, launches more high-value delivery systems like the Vystra pen, and maintains double-digit growth in its biologics segment.	BD's quarterly earnings calls, investor presentations, and press releases.	Google Trends: 'GLP-1 drug sales,' 'semaglutide therapy.' Industry news on pharmaceutical partnerships and drug delivery innovations.	IQVIA: GLP-1 drug sales data; Thinknum: Biologics/drug delivery job postings.
New Product Launches & Advanced Tissue Regeneration Trial	BD's innovation strategy focuses on attractive markets, and targeted commercial investments are accelerating growth in key platforms. Successful new product adoption and progress in clinical trials for advanced tissue regeneration are crucial for sustained top-line growth and future market expansion.	Specific revenue contributions or market share gains from newly launched products (Liverty TIPS Stent Graft, Elyra Thulium Fiber Laser System, Acumen IQ Plus Finger Cuff), continued double-digit growth in platforms like Advanced Patient Monitoring (APM) and PureWick, and updates on the progress and outcomes of the Landmark PREVENT Trial for advanced tissue regeneration.	Bullish if new product launches are cited as material contributors to segment growth or market share gains, if key growth platforms like APM and PureWick maintain double-digit growth rates, and if positive interim or final results are announced from the PREVENT Trial.	BD's quarterly earnings calls, investor presentations, and product-specific press releases.	Google Trends: search volume for 'Liverty TIPS,' 'Elyra Laser,' 'Acumen IQ Plus,' 'PureWick.' Industry forums for product reviews, clinical trial registries for PREVENT Trial updates.	Earnest Analytics: Sales data for new products; Similarweb: Web traffic to product pages; Thinknum: Sales/marketing job postings in relevant segments.
Alaris Remediation Headwind Resolution	The Alaris remediation has been a significant drag on BD's revenue growth and margins. Its resolution will remove a substantial headwind, allowing underlying growth drivers to contribute more significantly and improving overall financial performance.	Management's explicit confirmation in future earnings calls, particularly the FY27 guidance in November 2026, that the 200 basis point revenue headwind from Alaris has been fully removed.	Bullish if the 200 basis point revenue headwind from Alaris is confirmed to be fully removed in FY27, leading to an acceleration of overall revenue growth towards BD's mid-single-digit algorithm.	BD's quarterly earnings calls, investor presentations, and press releases, specifically the FY27 guidance provided in the November 2026 earnings call.	Industry news and regulatory updates on infusion pump market, FDA announcements related to Alaris.	Earnest Analytics: Alaris product sales trends; Thinknum: Alaris-related job postings.
BD Excellence Productivity Gains and AI Deployment	BD Excellence is a core operational strategy driving margin expansion through consistent productivity improvements. The deployment of AI across the supply chain represents a new, meaningful runway for further efficiency and cost savings, supporting long-term margin goals.	Reported gross productivity improvements in plants (e.g., maintaining or exceeding 8% quarterly), and updates on the deployment and quantifiable impact of the standardized digital platform for AI in the supply chain.	Bullish if BD continues to report strong gross productivity (e.g., 8% or higher) and provides concrete examples of AI-driven savings or efficiency improvements in supply chain or G&A functions.	BD's quarterly earnings calls and investor presentations.	Company career pages for AI/supply chain roles, industry reports on manufacturing efficiency and automation.	Thinknum: Supply chain/AI job postings growth; Gartner/IDC reports on enterprise AI adoption.
Stabilization of China and Vaccine Demand	China and vaccine demand have been identified as headwinds impacting BD's performance. Their stabilization and reduced drag on overall revenue will allow BD's underlying growth drivers to contribute more significantly to the top line.	Management commentary on vaccine order patterns and demand stabilization, and the actual revenue contribution from China (expected to drop to 3-4% of New BD revenue) in subsequent earnings reports.	Bullish if management confirms sustained stabilization or recovery in vaccine demand, and if China's revenue contribution is reported to be consistently at or below 3% of total New BD revenue, indicating a reduced drag on overall growth.	BD's quarterly earnings calls and investor presentations.	WHO/CDC reports on global vaccine demand, China economic data and healthcare market reports, industry reports on medical device market in China.	Macroeconomic data providers for China healthcare spending; IQVIA: Vaccine sales data.

Key Reported Metrics, Reratings Triggers & Results3 rows

The Alaris remediation creates a significant, but defined, headwind. Monitoring its impact is crucial for understanding underlying revenue growth and the timing

Upcoming print · 2026-11-05

Key reported metrics
Metric	Last period	Why it matters
Alaris Headwind Impact on Total Revenue	-1.0%	The Alaris remediation creates a significant, but defined, headwind. Monitoring its impact is crucial for understanding underlying revenue growth and the timing of its eventual removal, which will lift overall growth.
Adjusted Diluted EPS Growth	4.9%	Adjusted EPS is a key indicator of profitability and operational efficiency, reflecting the company's ability to translate revenue growth and productivity gains into shareholder value. Raised guidance signals confidence.
Total Revenue (FX-neutral) Growth	4.4%	This metric indicates the company's top-line performance, reflecting commercial momentum across growth platforms and overall market demand. Investors will watch for continued strength as the 'New BD' strategy unfolds.

Key Questions

Will BD's strong performance in growth platforms and operational efficiencies sufficiently mitigate the anticipated sequential deceleration in Q4 fiscal 2026 an

Will BD's strong performance in growth platforms and operational efficiencies sufficiently mitigate the anticipated sequential deceleration in Q4 fiscal 2026 and the 200 basis point Alaris headwind in fiscal 2027 to maintain its updated guidance?

Question 2: Can BD sustain the double-digit growth in its key platforms, particularly GLP-1 related biologics and newly launched products like Liverty and Elyra, to drive revenue acceleration beyond the Alaris headwind?
Question 3: To what extent will BD Excellence and the new AI deployment initiatives drive further operational productivity and margin expansion, effectively offsetting persistent tariff impacts and potential inflationary pressures?

Earnings Transcript SummaryTable

2026-08-06 · 2026Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Compete Strategy: Advancing commercial excellence, focusing on customer partnerships, accountability, faster decision-making, and converting portfolio strength into faster growth and sustainable share gains. This includes targeted commercial investments in high-growth areas like APM, UCC, and PI. 2. Innovate Strategy: Focusing the pipeline on attractive markets where BD's solutions are most needed, such as connected care, enabling the shift to lower-cost settings, and advancing treatment for specific chronic diseases. This involves increasing the cadence and speed of new product launches. 3. Deliver Strategy (Operational Excellence): Achieving operational excellence at scale through BD Excellence to improve quality, service, productivity, margin, and cash flow. This includes plant consolidations, raw material savings, waste reduction, and the deployment of a standardized digital platform for AI across the supply chain.	Call Takeaway & ToneThe overall takeaway of the call is that BD delivered a strong third fiscal quarter of 2026, exceeding expectations for revenue, adjusted operating margin, and adjusted EPS. The performance was broad-based, driven by strong execution across key growth platforms and the benefits of the 'New BD' strategy focusing on commercial excellence, innovation, and operational efficiency through BD Excellence. Management expressed confidence in continued momentum and raised full-year guidance. The tone of the call was positive and confident, with management emphasizing the strategic pillars and their ability to mitigate known headwinds like Alaris, China, and vaccine demand.	Prior Quarter'S Y/Y Growth By SegmentMedical Essentials: 1.7% growth; Connected Care: 3.3% growth; MMS: Not explicitly stated as a separate segment, but Connected Care (which includes MMS) grew 3.3%; BioPharma Systems: Not explicitly stated as a segment, but Biologics (a key driver within it) had double-digit growth; Interventional: 5.3% growth.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Strength in Q3 Performance and FY27 Outlook: Analysts questioned the broad-based strength in Q3, potential one-time factors, and how this momentum carries into FY27, especially regarding revenue guidance. Management (Tom Polen) responded that the strong growth was broad-based, driven by momentum in their growth platforms (many growing double-digits or high single-digits), and that they continue to invest commercially and in innovation, which also provides favorable mix benefits. For FY27, management (Vitor Roque) indicated a low single-digit revenue growth framework due to a 200 basis point Alaris headwind, but expected modest EPS leverage supported by pricing actions, productivity, and capital allocation. 2. Headwinds from the 10% of the Portfolio (Alaris, China, Vaccines): Analysts inquired about the trends, visibility on these headwinds ending, and other dragging line items. Management (Tom Polen) clarified that all three headwinds were playing out as expected. They noted positive signs of stabilization in vaccines, expecting to lap the headwind next quarter with preliminary order patterns not showing a repeat in FY27. China is a smaller portion of New BD's revenue (4%, likely dropping to 3%), and while a dynamic environment is assumed, its impact will be less significant. Alaris is a defined headwind (100 bps in FY26, 200 bps in FY27) that will cease thereafter. 3. Long-Term Operating Margin Expansion and Alaris Impact on Margins: Analysts pressed on the potential for further productivity enhancements, efficiency, and portfolio changes to drive operating margin expansion towards the end of the decade, and how the Alaris revenue headwind would impact margins. Management (Tom Polen and Vitor Roque) highlighted continued focus on revenue growth, positive mix benefits from growth platforms, and ongoing momentum from BD Excellence (8% productivity improvements quarterly). They also mentioned new initiatives like AI deployment for supply chain efficiency and G&A function improvements. While not providing a specific long-term target, they stated that Q4 margins would see enhancements despite the Alaris pressure, due to productivity gains, and that pricing actions, favorable mix, and BD Excellence would mitigate the natural drop-through of Alaris revenue decline in FY27.	Revenue SegmentsMedical Essentials: 3.2% growth; Connected Care: 4.4% growth; MMS: low single-digit growth; BioPharma Systems: 5.2% growth (mid-teens excluding vaccines); Interventional: 5.5% growth.

Transcript TidbitsTable

2026-08-06

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketBD expanded its vascular portfolio with the early European launch of the Liverty TIPS Stent Graft, entering a market that has seen limited innovation for many years and broadening BD's presence in the approximately $2 billion global venous market. The company also launched the Elyra Thulium Fiber Laser System, expanding its kidney stone portfolio and presence in the approximately $1.5 billion endourology market. Additionally, BD is expanding its noninvasive monitoring portfolio in APM with the Acumen IQ Plus Finger Cuff and Smart Pressure Controller, aiming to reach underserved OR and ICU patients. The company is in early stages of reimbursement for at-home PureWick, which is seen as an exciting future growth vector. BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs, including a new collaboration with EMS in Brazil for a semaglutide therapy utilizing the Vystra injection pen.	About CompetitionBD reported continued share gains in Alaris this quarter, up over 200 basis points year-to-date, and strong U.S. performance in MDS and specimen management driven by share gains. In specimen management, high single-digit growth was achieved through share gains across the BD Vacutainer portfolio, improved supply, and capitalizing on competitor back orders. The company is achieving high win rates across the biologics market, including GLP-1s. BD's scale, combined with BD Excellence embedded across its manufacturing network, is considered a growing competitive advantage.	About The Broader IndustryBD observes that healthcare is undergoing a significant transformation, becoming more connected, automated, and personalized. The company noted solid hospital utilization across its portfolio, reflected in strong U.S. MDS growth. An internal metric tracking the ratio of tubes sold to needles sold indicates an uptick in tube utilization versus needle utilization over the last couple of quarters, suggesting more diagnostic testing per patient. This trend could be due to higher acuity patients or new innovative cancer screening. The endourology market, valued at approximately $1.5 billion, is increasingly driven by disposables.	Where Things Are HeadedBD is updating its full-year guidance, now expecting revenue growth toward the high end of its low single-digit range and raising the midpoint of its adjusted EPS guidance. The company anticipates revenue growth to be toward the high end of its low single-digit FX-neutral range for fiscal '26, with currency expected to be a tailwind of about 100 basis points. Adjusted operating margin is expected to remain around 25%, inclusive of tariff impacts, and adjusted EPS guidance is updated to $12.62 to $12.72. For fiscal '27, BD expects low single-digit revenue growth, factoring in a 200 basis point headwind from the Alaris remediation ending in fiscal '26. The company anticipates modest EPS leverage in FY '27, supported by pricing actions, BD Excellence productivity gains, and capital allocation strategy. BD plans to continue investing in commercial and innovation to fuel growth for '28 and beyond. The company is seeing positive stabilization in vaccine demand and expects China's revenue contribution to drop to 3-4% of New BD revenue next year. BD will host an Investor Day soon to share more long-term targets. Future product drivers are expected in growth platforms like APM (including connecting APM monitoring and Alaris pumps), tissue regeneration (with new clinical trials), pharmacy automation, biologics (GLP-1s and novel biologics), Connected Care (Pyxis Pro, BD Incada), and PureWick (new products and reimbursement efforts for at-home use).	Updates On ThemeDiagnostics	Broader Themes EmergingThe deep integration of AI and machine learning is evolving beyond data analysis to directly influence assay development, computational pathology, and personalized treatment pathways. BD is investing in a standardized digital platform to run AI across its end-to-end supply chain for productivity and service improvement. AI is also being deployed to sales teams to enhance account visits and targeting. The company also mentioned a new AI platform, BD Incada.	Bullish-Leaning Quotes (Short)We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. Performance was broad-based, reflecting commercial momentum across our key growth platforms. More than 90% of the portfolio delivering high single-digit growth. We're winning more consistently, scaling our growth platforms faster and strengthening our position with customers around the world. We're up to 100 deals in the GLP-1 space.	Bearish-Leaning Quotes (Short)Growth was partially offset by known dynamics concentrated in less than 10% of our portfolio, primarily the difficult prior year comparison in Alaris as well as vaccines in China. Margins... were offset by approximately 110 basis points of tariff impact. Alaris remediation... creates a 200 basis points headwind next year. China is a much smaller portion of BD... going to probably drop into the 3s as the rest of the BD is growing faster.	HiringBD appointed Mike Feld as its first-ever Chief Revenue Officer. The company reallocated commercial headcount into high-growth spaces, making a $35 million incremental investment. This included growing the APM sales team by about 15% in the U.S., adding more sales headcount in UCC, and establishing a dedicated sales team for the VA channel for PureWick. The PI sales team also grew by 15% in the U.S. Mike Garrison, EVP and President of Medical Essentials and BioPharma Systems, announced his retirement, and Peter Menziuso joined as EVP and President of BD Interventional.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-06	Becton, Dickinson and Company (BDX) delivered a strong Q3 2026, surpassing expectations with broad-based growth and raised full-year guidance. Management expressed confidence in mitigating Alaris, China, and vaccine headwinds. The market reacted very positively, with BDX stock returning 3.63% (t+2 days), significantly outperforming SPY's 0.42%, aligning with the company's optimistic outlook.	Earnings Transcript	Neutral		+3.63% (vs SPY: +3.21%)

Upcoming EventsTable

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
BDX_03cb4ddc	by the end of the summer	2026-08-15	2026-09-22	Management expects to provide a clearer outlook on future vaccine demand and the stabilization of vaccine product sales.	Gaining better visibility into vaccine demand trends is crucial for assessing the future growth trajectory of the BioPharma Systems segment, as vaccine sales have been a notable drag on recent performance.	Ticker	2026-08-06	earnings_transcript